New drug cocktail targets Hard-to-Treat tumors
NCT ID NCT02264678
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new oral drug called ceralasertib, given alone or with other cancer treatments like chemotherapy or targeted drugs, in 354 adults with advanced solid tumors that no longer respond to standard care. The main goal is to check safety and find the best doses. Researchers are also looking at how the drug affects the body and whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ceralasertib
What this could lead to
If successful, this could help determine safe doses of ceralasertib combinations for treating advanced solid tumors.
What could go wrong
This is an early Phase 1 trial focused on safety, not yet on effectiveness. Many drug combinations may not work or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Irvine, California, 92618, United States
-
Research Site
Los Angeles, California, 90024, United States
-
Research Site
Los Angeles, California, 90089, United States
-
Research Site
Newport Beach, California, 92663, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Philadelphia, Pennsylvania, 19104, United States
-
Research Site
Bordeaux, 33076, France
-
Research Site
Lyon, 69373, France
-
Research Site
Saint-Herblain, 44805, France
-
Research Site
Villejuif, 94805, France
-
Research Site
Goyang-si, 10408, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03080, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 6351, South Korea
-
Research Site
Bristol, BS2 8ED, United Kingdom
-
Research Site
Cambridge, CB2 0QQ, United Kingdom
-
Research Site
Coventry, CV2 2DX, United Kingdom
-
Research Site
London, SW3 6JJ, United Kingdom
-
Research Site
London, W12 0HS, United Kingdom
-
Research Site
London, W1G 6AD, United Kingdom
-
Research Site
London, W1T 7HA, United Kingdom
-
Research Site
Manchester, M20 4GJ, United Kingdom
-
Research Site
Oxford, OX3 7LE, United Kingdom
-
Research Site
Sutton, SM2 5PT, United Kingdom
-
Research Site
Withington, M20 4BX, United Kingdom